Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma

NCT07529873 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

131

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck (SCCHN)

Interventions

DRUG: Ficerafusp alfa
DRUG: Nivolumab

Sponsor

Groupe Oncologie Radiotherapie Tete et Cou

Collaborators

[object Object]